There has been substantial investor interest in RLF-100 and its potential to treat not only COVID-19, but also Acute Respiratory Distress Syndrome related to sepsis, sarcoid lung disease, and other life-threatening pulmonary conditions.

You can find below a preprint providing insight into the mechanisms that underlie RLF-100 (Aviptadil). You may also want to watch some of the TV news stories that have aired about RLF-100.

NeuroRx is a private-held US company that is partnering with Relief in the development of RLF-100 and is also developing NRX-101 for the treatment of suicidal depression. If you would like to learn more about NeuroRx, please contact investors@neurorxpharma.com

The stock of Relief Therapeutics Holdings (SIX:RLF, OTC:RLFTF) trades on the Swiss Exchange and the US OTC exchange.

Useful information

Review Preprint

Gain scientific insight into the mechanisms that underlie RLF-100 (Aviptadil) and its potential to treat COVID-19 and other life-threatening pulmonary conditions.

Access Preprint
News

RLF-100 has been regularly covered by the news around the world. To learn more, review our most recent coverage on our news page.

RLF-100 News
About Relief Therapeutics

NeuroRx is a private-held US company that is partnering with Relief in the development of RLF-100. Relief Therapeutics Holdings (SIX:RLF, OTC:RLFTF) trades on the Swiss Exchange and the US OTC exchange. 

RLF Investor Information

Contact us for more information